NEW YORK--(BUSINESS WIRE)--Neuro-Hitech, Inc. (NASDAQ: NHPI), a New York-based biopharmaceutical company focused on developing innovative drugs for the treatment of neurodegenerative diseases, today announced that it had entered into an agreement with Numoda Corporation (“Numoda”) pursuant to which Numoda will review the results of Neuro-Hitechs’ recently completed Phase II clinical trial of Huperzine A in mild to moderate Alzheimer’s disease patients. After completing its review and delivering a report of its findings to Neuro-Hitech, Numoda will assist the Company in interpreting and presenting the results to potential licensing partners, purchasers and/or acquisition or merger candidates.
